U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Prostate Adenocarcinoma with Neuroendocrine Differentiation

MedGen UID:
271578
•Concept ID:
C1514506
•
Neoplastic Process

Definition

An invasive prostate adenocarcinoma characterized by the presence of malignant cells that exhibit neuroendocrine differentiation. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVProstate Adenocarcinoma with Neuroendocrine Differentiation

Professional guidelines

PubMed

Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R
Prostate 2024 Apr;84(5):426-440. Epub 2024 Jan 3 doi: 10.1002/pros.24664. PMID: 38173302
PEG10 is associated with treatment-induced neuroendocrine prostate cancer.
Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A
J Mol Endocrinol 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226. PMID: 31013476
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S, Inoue T, Ogawa O, Gleave ME
Int J Urol 2018 Apr;25(4):345-351. Epub 2018 Feb 3 doi: 10.1111/iju.13526. PMID: 29396873

Recent clinical studies

Etiology

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W
Nat Commun 2023 Nov 28;14(1):7794. doi: 10.1038/s41467-023-43676-3. PMID: 38016952Free PMC Article
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG
Cancer Cell 2023 Dec 11;41(12):2066-2082.e9. Epub 2023 Nov 22 doi: 10.1016/j.ccell.2023.10.009. PMID: 37995683Free PMC Article
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS, Attard G, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S
Lancet Oncol 2022 Nov;23(11):1398-1408. Epub 2022 Oct 18 doi: 10.1016/S1470-2045(22)00560-5. PMID: 36265504
Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ
J Clin Oncol 2018 Aug 20;36(24):2492-2503. Epub 2018 Jul 9 doi: 10.1200/JCO.2017.77.6880. PMID: 29985747Free PMC Article

Diagnosis

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM
J Clin Invest 2022 Nov 1;132(21) doi: 10.1172/JCI161858. PMID: 36317634Free PMC Article
Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
Liu S, Alabi BR, Yin Q, Stoyanova T
Semin Cancer Biol 2022 Nov;86(Pt 3):57-68. Epub 2022 May 18 doi: 10.1016/j.semcancer.2022.05.007. PMID: 35597438
Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T, Weber WA, Eiber M
J Nucl Med 2019 Sep;60(Suppl 2):13S-19S. doi: 10.2967/jnumed.118.220566. PMID: 31481583
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L, Vlachostergios PJ, Beltran H
Cold Spring Harb Perspect Med 2019 Feb 1;9(2) doi: 10.1101/cshperspect.a030593. PMID: 29844220Free PMC Article

Therapy

ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
Jing N, Zhang K, Chen X, Liu K, Wang J, Xiao L, Zhang W, Ma P, Xu P, Cheng C, Wang D, Zhao H, He Y, Ji Z, Xin Z, Sun Y, Zhang Y, Bao W, Gong Y, Fan L, Ji Y, Zhuang G, Wang Q, Dong B, Zhang P, Xue W, Gao WQ, Zhu HH
J Clin Invest 2023 Dec 15;133(24) doi: 10.1172/JCI168670. PMID: 38099497Free PMC Article
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.
Han M, Li F, Zhang Y, Dai P, He J, Li Y, Zhu Y, Zheng J, Huang H, Bai F, Gao D
Cancer Cell 2022 Nov 14;40(11):1306-1323.e8. Epub 2022 Nov 3 doi: 10.1016/j.ccell.2022.10.011. PMID: 36332622
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang XS, McCall SJ, Inman BA, Huang J
Eur Urol 2022 May;81(5):446-455. Epub 2022 Jan 17 doi: 10.1016/j.eururo.2021.12.039. PMID: 35058087Free PMC Article
Serotonin Pathway in Cancer.
Balakrishna P, George S, Hatoum H, Mukherjee S
Int J Mol Sci 2021 Jan 28;22(3) doi: 10.3390/ijms22031268. PMID: 33525332Free PMC Article
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ
J Clin Oncol 2018 Aug 20;36(24):2492-2503. Epub 2018 Jul 9 doi: 10.1200/JCO.2017.77.6880. PMID: 29985747Free PMC Article

Prognosis

Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG
Cancer Cell 2023 Dec 11;41(12):2066-2082.e9. Epub 2023 Nov 22 doi: 10.1016/j.ccell.2023.10.009. PMID: 37995683Free PMC Article
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM
J Clin Invest 2022 Nov 1;132(21) doi: 10.1172/JCI161858. PMID: 36317634Free PMC Article
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang XS, McCall SJ, Inman BA, Huang J
Eur Urol 2022 May;81(5):446-455. Epub 2022 Jan 17 doi: 10.1016/j.eururo.2021.12.039. PMID: 35058087Free PMC Article
Neuroendocrine neoplasms of the appendix, colon and rectum.
Volante M, Grillo F, Massa F, Maletta F, Mastracci L, Campora M, Ferro J, Vanoli A, Papotti M
Pathologica 2021 Feb;113(1):19-27. doi: 10.32074/1591-951X-230. PMID: 33686307Free PMC Article
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON
Science 2018 Oct 5;362(6410):91-95. doi: 10.1126/science.aat5749. PMID: 30287662Free PMC Article

Clinical prediction guides

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM
J Clin Invest 2022 Nov 1;132(21) doi: 10.1172/JCI161858. PMID: 36317634Free PMC Article
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL
Prostate 2020 Sep;80(12):1012-1023. Epub 2020 Jul 10 doi: 10.1002/pros.24035. PMID: 32649013Free PMC Article
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D
Nat Commun 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6. PMID: 31953400Free PMC Article
PEG10 is associated with treatment-induced neuroendocrine prostate cancer.
Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A
J Mol Endocrinol 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226. PMID: 31013476
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z
Am J Surg Pathol 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. PMID: 24145643Free PMC Article

Recent systematic reviews

Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, Shariat SF
Int J Mol Sci 2019 Mar 19;20(6) doi: 10.3390/ijms20061374. PMID: 30893781Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...